The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 12, 2022

Filed:

Jun. 09, 2014
Applicants:

Matthew J. Callaghan, Stanford, CA (US);

Christian S. Eversull, Palo Alto, CA (US);

Stephen A. Leeflang, Sunnyvale, CA (US);

Inventors:

Matthew J. Callaghan, Stanford, CA (US);

Christian S. Eversull, Palo Alto, CA (US);

Stephen A. Leeflang, Sunnyvale, CA (US);

Assignee:

LXS, LLC, Palo Alto, CA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61M 1/36 (2006.01); A61M 1/34 (2006.01); A61B 10/00 (2006.01);
U.S. Cl.
CPC ...
A61M 1/3653 (2013.01); A61B 10/0045 (2013.01); A61M 1/3496 (2013.01); A61M 1/367 (2013.01); A61M 1/3609 (2014.02); A61M 1/3615 (2014.02); A61M 1/3659 (2014.02); A61M 2202/0405 (2013.01); A61M 2205/3306 (2013.01); A61M 2205/3317 (2013.01); A61M 2230/207 (2013.01); A61M 2230/208 (2013.01);
Abstract

System and methods are provided for treating a patient that include a delivery device sized for introduction into a target site within a patient's body, a source of one or more therapeutic and/or diagnostic agents coupled to the delivery device, and a tubular member sized for introduction into the patient's vasculature to isolate the thoracic duct. Once the thoracic duct is isolated, fluid may be removed from the thoracic duct, e.g., to prevent the agents that transit from the target site into the thoracic duct from entering the patient's vasculature, and/or to modulate flow through the thoracic duct to modulate concentration and/or resident time of the agents at the target site. The one or more agents may include particles sized for preferential transit into the lymphatic system.


Find Patent Forward Citations

Loading…